Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 1997

View Archived Issues

Genome Therapeutics: Q4 and FY 1997 highlights

Diatide: Q3 1997 highlights

Connetics: Q3 1997 highlights

Sepracor: Q3 1997 highlights

Genzyme General: Q3 1997 highlights

Roussel Morishita reports antiulcer agents with a novel mechanism of action

BE-52440A and BE-52440B: novel antitumor antibiotics reported in patent literature

Vaxcel: Q3 1997 highlights

OP-1 effective in preclinical model of stroke

New compound isolated from the African tarantula by Neurex

Gene for estrogen receptor-postive cancers available for licensing

ID Vaccine and the NIAID collaborate on GAS vaccine

Angiogenesis-inhibitory peptides available for licensing from NIH

Antiprogestational agents available from the NIH

rPAF-AH proceeds to phase II for asthma

IntraBiotics codevelops IB-367 with Pharmacia & Upjohn

CoCensys licenses small molecules with anticonvulsant and potential analgesic effects

Phase Ia trial of ADCI successfully completed

CNS-5161 clinical update

Johnson & Johnson and Japan Tobacco sign licensing agreement

HMR discloses azasteroids for estrogen/androgen-mediated disorders

Antimicrobial GE-2270 derivatives from Biosearch

Lexipafant as adjunct for severe acute pancreatitis

Temozolomide: phase II efficacy and tolerability data in patients with high-grade glioma

Takeda discovers new Taxol-like compound

First oral, tumor-activated anticancer drug filed by Roche

New immunomodulators for treating rheumatoid arthritis

New neurotransmitter implicated in hunger and satiety

Mechanism of glucocorticoid antiinflammatory effects elucidated

New tumor contrast agents disclosed

Recordati's lercanidipine launched in The Netherlands

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...